SIEHM Trademark

Trademark Overview


On Monday, March 22, 2021, a trademark application was filed for SIEHM with the United States Patent and Trademark Office. The USPTO has given the SIEHM trademark a serial number of 90593624. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Saturday, February 15, 2025. This trademark is owned by Eli Lilly and Company. The SIEHM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
siehm

General Information


Serial Number90593624
Word MarkSIEHM
Filing DateMonday, March 22, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateSaturday, February 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 3, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 24, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, March 25, 2021NEW APPLICATION ENTERED
Thursday, June 24, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 5, 2021NON-FINAL ACTION E-MAILED
Thursday, November 4, 2021ASSIGNED TO EXAMINER
Friday, November 5, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 5, 2021NON-FINAL ACTION WRITTEN
Tuesday, March 8, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 8, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 8, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 25, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, March 27, 2022ASSIGNED TO LIE
Tuesday, March 29, 2022LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, May 3, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, April 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 3, 2022PUBLISHED FOR OPPOSITION
Tuesday, June 28, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 15, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, November 23, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 23, 2022SOU EXTENSION 1 FILED
Wednesday, November 23, 2022SOU EXTENSION 1 GRANTED
Friday, November 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 2, 2022ASSIGNED TO EXAMINER
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 15, 2023SOU EXTENSION 2 FILED
Monday, May 15, 2023SOU EXTENSION 2 GRANTED
Wednesday, May 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU EXTENSION 3 FILED
Monday, November 13, 2023SOU EXTENSION 3 GRANTED
Wednesday, November 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 16, 2024SOU EXTENSION 4 GRANTED
Thursday, May 16, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 16, 2024SOU EXTENSION 4 FILED
Friday, May 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 19, 2024SOU EXTENSION 5 FILED
Tuesday, November 19, 2024SOU TEAS EXTENSION RECEIVED
Saturday, February 15, 2025SOU EXTENSION 5 GRANTED
Sunday, February 16, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, February 15, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL